Abstract
Background: Erlotinib-HCl is a quinazoline derivative used as a first line drug in the treatment of advanced non-small-cell lung cancer. Conventionally, erlotinib HCl tablets has poor solubility in water and its dissolution is much lower in the fasting state as compared to the fed state. Oral absorption of erlotinib HCl is higher when administered with food. It is due to food which delays the gastric emptying time and allows more time for erlotinib HCl to exposes to fat in which it is more soluble. Thus, oral bioavailability of erlotinib HCl in fasting state has limitation in comparison to fed state, it affect the therapeutic efficacy of erlotinib HCl. Therefore, there is a need to improve art of delivery of erlotinib HCl which can overcome bioavailability issues. In the present study, we formulated dendrimers based formulation in order to improve its PK-PD profiles.
Methods: Methods described in detail in the article for design and synthesis of Silica based Erlotinib dendrimer which was further evaluated mechanistically for bio efficacy and its toxicities.
Results: The quinazoline dendrimer had an effective average particle size of about 100-1000 nm with drug loading efficiency of 0.571% and encapsulation efficiency was 38 %. In vitro cytotoxicity against panel of EGFR overexpressing cell line reveals lowest IC50 values 3.4 µM in A431 cell line, whereas 0.2 µM for NCI-H322 cell line. To assess the effect on DNA cell cycle by test material hypo diploid sub-G1 DNA fraction (<2n DNA) of the cells measured in treated cells using flowcytometer at 0.5, 1, 1.5 µM and was found to be 21.5, 15.4 and 17.2% respectively. The loss of mitochondrial membrane potential indicate it induces programmed cell death in cells via intrinsic pathway. Induction of genotoxic DNA damage indicate that dendrimer treated NCI-H322 cells resulted formation of comets with head DNA of 69.95 and 41.4% at concentration 0.5 and 1.5 µM respectively.
Conclusion: In vitro results of dendrimer based nano scaled formulation showing promising results as compared to the free drug reveal that the formulation can further be evaluated for development as alternative delivery system.
Keywords: Dendrimer, Erlotinib HCl, NSCLC (Non-Small-Cell Lung Cancer).
Graphical Abstract
Pharmaceutical Nanotechnology
Title:Dendrimer Based Formulation of Erlotiniib HCl: Development, Characterization and In-Vitro Evaluation
Volume: 3 Issue: 4
Author(s): Rachna D. Singh, Vaibhav Khare, Farnaz Yusuf, Abid Hamid, Asha Chaubey and Shashank Singh
Affiliation:
Keywords: Dendrimer, Erlotinib HCl, NSCLC (Non-Small-Cell Lung Cancer).
Abstract: Background: Erlotinib-HCl is a quinazoline derivative used as a first line drug in the treatment of advanced non-small-cell lung cancer. Conventionally, erlotinib HCl tablets has poor solubility in water and its dissolution is much lower in the fasting state as compared to the fed state. Oral absorption of erlotinib HCl is higher when administered with food. It is due to food which delays the gastric emptying time and allows more time for erlotinib HCl to exposes to fat in which it is more soluble. Thus, oral bioavailability of erlotinib HCl in fasting state has limitation in comparison to fed state, it affect the therapeutic efficacy of erlotinib HCl. Therefore, there is a need to improve art of delivery of erlotinib HCl which can overcome bioavailability issues. In the present study, we formulated dendrimers based formulation in order to improve its PK-PD profiles.
Methods: Methods described in detail in the article for design and synthesis of Silica based Erlotinib dendrimer which was further evaluated mechanistically for bio efficacy and its toxicities.
Results: The quinazoline dendrimer had an effective average particle size of about 100-1000 nm with drug loading efficiency of 0.571% and encapsulation efficiency was 38 %. In vitro cytotoxicity against panel of EGFR overexpressing cell line reveals lowest IC50 values 3.4 µM in A431 cell line, whereas 0.2 µM for NCI-H322 cell line. To assess the effect on DNA cell cycle by test material hypo diploid sub-G1 DNA fraction (<2n DNA) of the cells measured in treated cells using flowcytometer at 0.5, 1, 1.5 µM and was found to be 21.5, 15.4 and 17.2% respectively. The loss of mitochondrial membrane potential indicate it induces programmed cell death in cells via intrinsic pathway. Induction of genotoxic DNA damage indicate that dendrimer treated NCI-H322 cells resulted formation of comets with head DNA of 69.95 and 41.4% at concentration 0.5 and 1.5 µM respectively.
Conclusion: In vitro results of dendrimer based nano scaled formulation showing promising results as compared to the free drug reveal that the formulation can further be evaluated for development as alternative delivery system.
Export Options
About this article
Cite this article as:
Singh D. Rachna, Khare Vaibhav, Yusuf Farnaz, Hamid Abid, Chaubey Asha and Singh Shashank, Dendrimer Based Formulation of Erlotiniib HCl: Development, Characterization and In-Vitro Evaluation, Pharmaceutical Nanotechnology 2015; 3 (4) . https://dx.doi.org/10.2174/2211738504666160213001218
DOI https://dx.doi.org/10.2174/2211738504666160213001218 |
Print ISSN 2211-7385 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-7393 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Integrative Analysis of Dysfunctional Modules Driven by Genomic Alterations at System Level Across 11 Cancer Types
Combinatorial Chemistry & High Throughput Screening Physico-chemical and Biological Evaluation of Flavonols: Fisetin, Quercetin and Kaempferol Alone and Incorporated in beta Cyclodextrins
Anti-Cancer Agents in Medicinal Chemistry Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Incidentally Detected Increased FDG Uptake in Bowel and its Correlation with Hystopathological Data: Our Experience in a Case Series Study
Current Radiopharmaceuticals Genetic Susceptibility to Endometrial Cancer
Current Women`s Health Reviews LDH Nanocontainers as Bio-Reservoirs and Drug Delivery Carriers
Recent Patents on Nanotechnology Modeling of the Desialylated Human Serum N-glycome for Molecular Diagnostic Applications in Inflammatory and Malignant Lung Diseases
Current Molecular Medicine Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry Synthesis, Topoisomerase I Inhibitory and Cytotoxic Activities of Chromone Derivatives
Medicinal Chemistry New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Progress and Related Patents on the Applications of Bone Marrow-Derived Stem/Progenitor Cells in Regenerative Medicine and Cancer Therapies
Recent Patents on Regenerative Medicine Potential New Anticancer Molecular Targets for the Treatment of Human Testicular Seminomas
Mini-Reviews in Medicinal Chemistry Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review
Current Drug Targets Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy
Current Cancer Therapy Reviews Therapeutic Perspectives for cN-II in Cancer.
Current Medicinal Chemistry New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2
Current Medicinal Chemistry - Anti-Cancer Agents Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry A Novel Adaptive PET/CT Image Fusion Algorithm
Current Bioinformatics